{"id":"https://openalex.org/W2965845866","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.7178","title":"Erlotinib as first-line treatment for untreated advance stage NSCLC with good prognosis","display_name":"Erlotinib as first-line treatment for untreated advance stage NSCLC with good prognosis","publication_year":2006,"publication_date":"2006-06-20","ids":{"openalex":"https://openalex.org/W2965845866","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.7178","mag":"2965845866"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2006.24.18_suppl.7178","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.7178","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.24.18_suppl.7178","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016686763","display_name":"Wallace Akerley","orcid":"https://orcid.org/0000-0002-3090-4778","observed_orcids":["https://orcid.org/0000-0002-3090-4778"]},"institutions":[{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"W. L. Akerley","raw_affiliation_strings":["Huntsman Cancer Institute, Salt Lake City, UT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Huntsman Cancer Institute, Salt Lake City, UT","institution_ids":["https://openalex.org/I2801159745"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5016686763"],"corresponding_institution_ids":["https://openalex.org/I2801159745"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":"18_suppl","first_page":"7178","last_page":"7178"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ib","display_name":"ib","score":0.9190000295639038},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8980000019073486},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7699999809265137},{"id":"https://openalex.org/keywords/advanced-non-small-cell-lung-cancer","display_name":"advanced non-small cell lung cancer","score":0.6370000243186951},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.5820000171661377},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7680000066757202},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.5460000038146973},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.7670000195503235},{"id":"https://openalex.org/keywords/performance-status","display_name":"performance status","score":0.4959999918937683},{"id":"https://openalex.org/keywords/tumor-aggressiveness","display_name":"tumor aggressiveness","score":0.39899998903274536},{"id":"https://openalex.org/keywords/recurrent-nsclc","display_name":"recurrent NSCLC","score":0.550000011920929},{"id":"https://openalex.org/keywords/stage-iiib-iv-nsclc","display_name":"stage IIIB/IV NSCLC","score":0.8799999952316284},{"id":"https://openalex.org/keywords/never-smokers","display_name":"never smokers","score":0.4449999928474426}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9186551570892334},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.8711135387420654},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6979769468307495},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.6634536981582642},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6495723128318787},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6427338123321533},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5485721826553345},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4682539403438568},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.46798205375671387},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.42283114790916443},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3677957057952881},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34604305028915405},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.26269349455833435},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.1259281039237976},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2006.24.18_suppl.7178","doi":"https://doi.org/10.1200/jco.2006.24.18_suppl.7178","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2006.24.18_suppl.7178","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2338992664","https://openalex.org/W2547770173","https://openalex.org/W1991406121","https://openalex.org/W2513139247","https://openalex.org/W2242356173","https://openalex.org/W2468266227","https://openalex.org/W7036623501","https://openalex.org/W2379114046","https://openalex.org/W2352792612","https://openalex.org/W2350859467"],"abstract_inverted_index":{"7178":[0],"Background:":[1],"Erlotinib":[2],"demonstrated":[3],"improved":[4],"survival":[5,14],"in":[6,15,60,167,172,175,186,189,193,196,202,205,208],"previously":[7],"treated":[8],"NSCLC,":[9,81],"but":[10],"did":[11],"not":[12],"affect":[13],"untreated":[16],"NSCLC":[17,157],"when":[18],"used":[19],"with":[20,37,65,223,229,236,301,334],"concurrent":[21],"chemotherapy.":[22,116,124],"A":[23],"potential":[24],"hypothesis":[25],"for":[26,35,85,216,263,280,344],"this":[27],"paradox":[28],"is":[29],"erlotinib":[30,56,102,258,316,323],"may":[31,324],"be":[32,325],"more":[33],"effective":[34,327],"patients":[36,64,127,242],"less":[38,66,93,335],"aggressive":[39,67],"tumors":[40,68],"(i.e.":[41],"those":[42],"still":[43,288,304],"surviving":[44],"after":[45,122],"multiple":[46],"chemotherapy":[47,59,84,248,281,333],"treatments).":[48],"The":[49,117,131,161,254,275,291],"current":[50],"trial":[51],"was":[52,120,134,164,259],"designed":[53],"to":[54,115,246,250,352],"evaluate":[55],"before":[57,111],"initial":[58,332],"a":[61],"population":[62],"of":[63,315],"based":[69],"on":[70,257,289],"clinical":[71],"criteria.":[72],"Methods:":[73],"Eligibility":[74],"criteria":[75],"included":[76,182],"stage":[77],"IIIB/IV":[78],"or":[79,108],"recurrent":[80],"no":[82,97],"prior":[83],"systemic":[86],"disease,":[87],"PS":[88,138],"=":[89,139,273],"0\u20131,":[90],"weight":[91],"loss":[92],"than":[94],"10%,":[95],"and":[96,144,198,234,277,285,293,299,329,337],"urgent":[98],"symptoms.":[99],"Patients":[100],"received":[101],"150":[103],"mg":[104],"po/day":[105],"until":[106],"objective":[107],"symptomatic":[109],"progression":[110,239],"they":[112],"were":[113,142,146,243],"switched":[114],"10":[118],"endpoint":[119],"time-to-progression":[121],"1st":[123],"Results:":[125],"40":[126],"have":[128,211],"been":[129,212],"accrued.":[130],"median":[132,255,276,292],"age":[133],"65,":[135],"35":[136],"had":[137],"1,":[140,194,206],"8":[141,228,260,267],"never-smoker,":[143],"23":[145],"former":[147],"smokers.":[148],"Histologies":[149],"were:":[150],"Adeno":[151],"20,":[152],"BAC":[153],"2,":[154,187],"Sq":[155],"6,":[156],"11,":[158],"Other":[159,180],"1.":[160],"major":[162],"toxicity":[163,181,336],"rash":[165,264],"(Gr0":[166],"4,":[168],"Gr1in":[169],"15,":[170],"Gr2":[171,188,195,204],"14,":[173],"Gr3":[174,207],"3,":[176],"4":[177,221],"too":[178,244],"early.":[179],"liver":[183],"(Gr":[184],"1":[185],"1),":[190],"mucositis":[191],"(Gr1":[192,201],"1)":[197],"diarrhea":[199],"(liver":[200],"10,":[203],"2).":[209],"34":[210],"followed":[213],"long":[214],"enough":[215],"response":[217],"evaluation,":[218],"which":[219],"identified":[220],"(12%)":[222],"PR":[224],"(median":[225,231],"37":[226],"wks),":[227],"stable":[230],"20":[232],"wk)":[233],"22":[235,283],"progression.":[237],"At":[238],"only":[240],"2":[241],"ill":[245],"start":[247],"due":[249],"inadequate":[251],"performance":[252],"status.":[253],"time":[256],"wks":[261,271,284,298],"overall:":[262],"Gr":[265,269],"0\u20131":[266],"wks,":[268],"2\u20133=43":[270],"(p":[272],"0.03).":[274],"6-month":[278],"PFS":[279],"are":[282,296],"45%":[286],"with17":[287],"treatment.":[290],"1-yr":[294],"survivals":[295],"50":[297],"47%":[300],"24":[302],"pts":[303],"alive.":[305],"Conclusions:":[306],"Mid-term":[307],"safety":[308],"analyses":[309],"exceeded":[310],"expectations.":[311],"Rash":[312],"predicts":[313],"duration":[314],"effectiveness.":[317],"Preliminary":[318],"results":[319],"suggest":[320],"single":[321],"agent,":[322],"as":[326,331,341],"(PFS":[328],"survival)":[330],"merits":[338],"randomized":[339],"testing":[340],"first":[342],"treatment":[343],"advanced":[345],"lung":[346],"cancer.":[347],"No":[348],"significant":[349],"financial":[350],"relationships":[351],"disclose.":[353]},"counts_by_year":[],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2019-08-13T00:00:00"}